These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Dang TO, Ogunniyi A, Barbee MS, Drilon A. Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948 [Abstract] [Full Text] [Related]
4. Emerging drugs for squamous cell lung cancer. Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R. Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559 [Abstract] [Full Text] [Related]
5. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A. Cell Death Dis; 2015 Aug 06; 6(8):e1850. PubMed ID: 26247735 [Abstract] [Full Text] [Related]
7. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. Sacher AG, Gandhi L. JAMA Oncol; 2016 Sep 01; 2(9):1217-22. PubMed ID: 27310809 [Abstract] [Full Text] [Related]
8. A decade of advances in treatment for advanced non-small cell lung cancer. Gettinger S, Lynch T. Clin Chest Med; 2011 Dec 01; 32(4):839-51. PubMed ID: 22054890 [Abstract] [Full Text] [Related]
10. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y. J Thorac Oncol; 2013 Feb 01; 8(2):161-70. PubMed ID: 23287853 [Abstract] [Full Text] [Related]
15. Emerging drugs targeting PD-1 and PD-L1: reality or hope? Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C. Expert Opin Emerg Drugs; 2014 Dec 01; 19(4):557-69. PubMed ID: 25253438 [Abstract] [Full Text] [Related]
16. Onartuzumab in lung cancer: the fall of Icarus? Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Expert Rev Anticancer Ther; 2015 May 01; 15(5):487-9. PubMed ID: 25818471 [Abstract] [Full Text] [Related]
17. New antiangiogenetic agents and non-small cell lung cancer. Gridelli C, Rossi A, Maione P. Crit Rev Oncol Hematol; 2006 Oct 01; 60(1):76-86. PubMed ID: 16843002 [Abstract] [Full Text] [Related]